Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: gbh who wrote (243)	6/23/1998 5:54:00 PM
From: gbh	Respond to of 410

Market For Cardiac Devices Set to Increase to $11.8 Billion By 2001, Says Clinica's Latest Cardiovascular Report RICHMOND, UK, June 22 /PRNewswire/ -- The CVD market is still proving to be an attractive market for new entrants. Developments in less invasive surgery techniques and devices, plus a global increase in the occurrence of cardiovascular disease have led to a sustained interest in the market for new products. Cardiovascular disease is the predominant cause of premature death in the developed countries of the world. The populations of developed nations are aging and emerging nations are embracing Western lifestyles that will eventually lead to a massive increase in CVD in these countries -- many of these nations already have large, wealthy middle classes readily able to afford high quality medical care. Recent treatments for cardiovascular disease are examined in a new title from Clinica Reports. ''Clinica's Complete Guide to Cardiovascular Devices'' includes the cardiovascular devices that are employed for the treatment of CVDs are numerous and varied and the report focuses on those most commonly used, i.e. PTCA systems, vascular stents, atherectomy devices, implantable pacemakers, implantable defibrillators, cardiac ablation catheters, prosthetic heart valves, vascular grafts, cardiovascular repair fabrics and PTA systems. Key participants in this market that are profiled in this report are: Ave Inc., CR Bard, Baxter International, Boston Scientific Corp [NYSE:BSX - news], Guidant, Johnson & Johnson,Medtronic, Schneider, St. Jude Medical, Sulzer Medica, Ventritex. Profiles include an informative company overview, details of financial performance and sales of devices by geographic area, product descriptions and details of R&D activity. Clinica's Complete Guide to Cardiovascular Devices Price: pounds sterling 495 / US$1,040.

To: gbh who wrote (243)	6/23/1998 6:01:00 PM
From: gbh	Read Replies (2) \| Respond to of 410

From Yahoo message board. I don't know about the reliability. messages.yahoo.com@m2.yahoo.com AVEI Management Provides Revenue Guidance for Qtr DustyRoads91 Jun 22 1998 5:01PM EDT I spoke today with stock analyst who called AVEI management late last week. Company provided guidance indicating that quarter will exceed $170 MM and will exceed current market consensus for earnings estimates. Company currently producing at capacity -- which they are shipping immediately. No inventory buildup is occurring. Following formal earnings release, stock analyst expects Goldman and others to INCREASE EPS estimates for Calendar 98 and next Fiscal 99 periods. NIR vs GFX: GS and others have canvassed cath labs and the consensus is that each technology (NIR vs GFX) will acquire an equal market share (approx)in the future; in the face of this information, GS and others believe that AVEI will continue earnings growth into 1999 and beyond. Goldman and Others are perplexed at the market reaction in the face of solid current earnings, opinions of professionals interviewed in cath labs and buyout valuation of AVEI (approx $55.00) Current TA is negative with probable $27.00 before $30.00